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A B S T R A C T
The mortality associated with end-stage heart failure (HF) is high despite the development of new and
increasingly effective drugs and non-pharmacological therapies. Repetitive hospitalizations predict fatal
outcomes and each hospitalization should prompt individual conversations with the patient, the family,
and the caregivers. A multidisciplinary disease management program promotes the education of
patients and their families and modiﬁes their behavior, with a view to ultimately improve the prognosis
and quality of life. From the early to the late stages of HF, a multidisciplinary disease management
program should be implemented. In Western societies this multidisciplinary management has long been
debated and endorsed, in contrast to Japan, where it has just begun. In 2012, the Japanese Nursing
Association launched a certiﬁcation in chronic HF nursing. A Japanese version of HF disease management
should soon be developed in its own social environment.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
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when discussion with individual patients, their relatives, and the
caregivers should take place. A disease management program is a
multidisciplinary approach, which promotes the education of the
patient and their relatives, and modiﬁes the behavior with an
ultimate goal to improve the prognosis [5,6]. Despite the recom-
mendation of several pharmacological treatments by professional
practice guidelines, the performance of individual medications is
highly variable among medical institutions, and might be increased
by the implementation of a multidisciplinary management program.gy.
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the preservation of quality of life (QOL) becomes particularly
important [7–9]. At this point, the objectives of the multidisciplinary
approach may also change. The medical therapy recommended by
the guidelines might have to be discontinued because of side effects,
such as hypotension and renal failure. Moreover, some patients may
need palliative interventions, including opiates. These choices must
be individually re-evaluated by the multidisciplinary team. In
Western societies this form of multidisciplinary management has
been adopted and debated for decades. In contrast, it is just
beginning in Japan. In 2012, the Japanese Nursing Association
created a certiﬁcation in chronic HF nursing. This review discusses
the role of multidisciplinary interventions in the context of Japanese
medicine.
Members of the team, sites of activity, and clinical endpoints
Members of the team
While the role of multidisciplinary teams in the treatment of
patients with HF has been described, the individual team members
have been less clearly characterized and the members of
multidisciplinary teams vary among institutions [5,6]. However,
the main members of the teams are doctors and nurses. In Western
societies, internists, family physicians, or general practitioners are
sometimes included beside cardiologists. Lee et al. reported that
collaborative care of HF by a cardiologist and primary care
physician within 30 days after discharge of the patient from the
hospital was associated with superior outcomes [10]. The nursing
staff is hospital-based and specialized in the management of HF, as
well as in charge of cardiac rehabilitation and home care [5,6]. The
pharmacist educates patients in the use of medications and
dispenses information regarding medical therapies to the multi-
disciplinary team members, helping patients follow the therapeu-
tic guidelines and promoting medical compliance. Koshman et al.
reported the results of a meta-analysis and pharmaceutical care in
the treatment of patients with HF. Since all-cause mortality and
hospitalizations for management of HF were lowered, they
concluded that the inclusion of pharmacists in the HF care team
should be strongly considered [11]. Other health professionals,
such as dieticians, physical therapists, and social workers might
also be included. The dietician should explain what type of food
should be consumed to lower the risk of adverse cardiovascular
events, as dietary indiscretions are known to precipitate the
readmission of patients to the hospital. Nutritional interventions
may also be important in the support of cachectic patients. In
Japan, the current composition of multidisciplinary teams includes
cardiologists, certiﬁed nurses, pharmacists, physical therapists,
and dieticians [12].
Sites of activity
The work place of multidisciplinary management teams is
divided between hospital and ambulatory settings. Out-of-hospital
places include ambulatory facilities, homes, and telemonitoring.
Jencks et al. reported that the 30-day rehospitalization rate of US
Medicare beneﬁciaries suffering from HF was 26.9% [13]. Since the
risk of rehospitalization is high just after the patients’ discharge
from the hospital, a seamless in and out of hospital disease
management program is crucial. A thorough discharge education is
critical [14] and an outpatient-based disease management
program should be enforced [15]. Telemonitoring might help
implement the multidisciplinary approach when access is limited
by geographical constraints. The Telemonitoring to Improve Heart
Failure Outcomes (Tele-HF) study failed to signiﬁcant decrease the
rates of all-cause re-hospitalizations and deaths [16]; however, arecent meta-analysis, which excluded Tele-HF, showed a trend
toward a decrease in all-cause mortality conferred by a structured
telephone support program [17]. Further studies are necessary to
conﬁrm these observations. New means of remote monitoring with
implantable cardioverter deﬁbrillators (ICD) with or without
resynchronization therapy are promising [18]. The Evolution of
Management Strategies of Heart Failure Patients With Implantable
Deﬁbrillators (EVOLVO) study found that remote monitoring
reduced the number of emergency visits and the overall
consumption of healthcare resources [19].
The Japanese Heart Failure Outpatients Disease Management
and Cardiac Evaluation (J-HOMECARE) study observed improve-
ments in the patients’ psychological status and lower hospitaliza-
tion rates by a disease management program led by home visiting
nurses [20]; the Home telemonitoring study for Japanese patients
with heart failure (HOMES-HF) is in progress [21].
Endpoints
Among clinical endpoints, morbidity and mortality represent
the gold standards [22]; however, an accurate assessment of the
effects of multidisciplinary interventions on these endpoints is
challenging, as the patients present with complicated illnesses
often requiring multiple hospitalizations. McAlister et al. reported
that multidisciplinary strategies lowered the rate of hospitaliza-
tions for HF and all-cause hospitalizations, although they had no
effect on mortality [23]. In the Coordinating Study Evaluating
Outcomes of Advising and Counseling in Heart Failure (COACH)
study, management of the disease by trained nurses did not lower
the rates of death and hospitalization for HF [24]. The effectiveness
of a multidisciplinary team is sometimes ascertained by the use of
evidence-based therapy, the number of hospitalizations, the
consumption of resources, functional capacity, QOL, and patient-
reported health outcomes [25–28].
Depression is common in HF and contributes to poor outcomes
[29,30]. Change in the severity of depression was a primary
endpoint in the Sertraline Against Depression and Heart Disease in
Chronic Heart Failure (SADHART-CHF) trial [31], while changes in
QOL, depression, and anxiety were the primary endpoints in the
randomized Management of Sadness and Anxiety in Cardiology
(MOSAIC) trial [32].
Besides the disease characteristics, socio-environmental
factors also play an important role. Tsuchihashi et al. reported
that irregular follow-ups, weak professional support, and
unemployment are also predictors of poor prognosis in Japanese
patients, and might be targets to lower mortality and morbidity
[33].
Tool kits
The implementation of multidisciplinary team management is
greatly facilitated by a tool kit, providing patients with a uniform
education by nurses in or out of the hospital, pharmacists, and
cardiologists and family physicians. For example, the Improve the
Use of Evidence-Based Heart Failure Therapies in the Outpatient
Setting (IMPROVE HF) study provided evidence of improved
management of ambulatory patients suffering from HF, based on a
best-practices algorithm, clinical pathway, standard encounter
forms, checklists, and pocket cards [34]. A textbook on HF was
released by our institution in 2012 (Fig. 1a). It teaches the
pathophysiology, medical treatment, life style modiﬁcation, and
self-monitoring and self-management of HF, including abundant
illustrations. The Japanese Heart Failure Society also released
another textbook (http://www.asas.or.jp/jhfs/topics/20130301.
html) (Fig. 1b). While a critical pathway may be an option to
strengthen the therapeutic guidelines [35], such a critical pathway
Fig. 1. Book covers on heart failure from our institution (a) and from the Japanese Heart Failure Society (b). Both books were released in 2012 and are widely available at no
cost in Japan. Each book has an illustrated text and a daily checklist. (c) Explanation of the need for treatment with angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers. (d) Representative page of the book from our institution.
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A conference with the multidisciplinary members of the team is
important to (1) share patient information, including social and
family background, (2) set an appropriate treatment goal at each
stage of the disease, and (3) promote access to new devices or new
pharmaceuticals. And feedback of the case report is critical to go
forward and improve the system.
Interventions
Disease management program
While the progression of HF is, in itself, a cause of rehospitali-
zation, several factors are reversible, such as a lack of understand-
ing of the disease, imprudent diet, non-compliance with treatment,
disorganized follow-ups, and difﬁcult access to specialized care of
cardiac decompensation. Thus, a comprehensive intervention
program is needed that facilitates the implementation of therapy
recommended by professional practice guidelines and addresses
behavioral changes [5,6,36].
A disease management program is an approach to patient care
that emphasizes a coordinated, all-inclusive care, along the
continuum of disease and across the healthcare delivery system,
using multidisciplinary techniques to improve the quality and
cost-effectiveness, and lower the risk of re-hospitalization for HF.
The guidelines of the Heart Failure Society of America and
European Society of Cardiology (ESC) recommend a management
program that focuses on lifestyle changes, symptom recognition by
patients, and consultation with healthcare professionals for
changes in symptoms. They include psychological support for
patients, their relatives, and their caregivers [37,38]. The guide-
lines of the Japanese Circulation Society also emphasize the
importance of implementing a disease management program [39],
the structure of which may vary depending on the institution.
However, studies have shown that a HF management program
cannot systematically decrease the incidence of adverse cardiac
events [24]. The required intensity, duration, and long-term effects
of the interventions, as well as the most appropriate endpoints are
unknown.
Self-care management requires that patients recognize a
change in congestive symptoms, evaluate the change, decide to
take action, contact the healthcare providers when needed, and
evaluate the response to the treatment. A scientiﬁc statement from
the American Heart Association (AHA) speciﬁes self-care behavior,
such as medication taking, symptom monitoring, dietary prudence,
ﬂuid and alcohol limitations, weight loss due to cachexia, daily
exercise, smoking cessation, and preventive measures [40]. The
ESC also issued practical guidelines for self-care management of HF
[41]. However, the recent Heart Failure Adherence and Retention
Trial (HART) found no decrease in the rates of death or
hospitalizations for HF conferred by self-management [42]. There-
fore, it should not be implemented in isolation rather than as part
of a comprehensive multidisciplinary program.
Optimizing medical treatment
Angiotensin-converting enzyme (ACE) inhibitors and beta-
adrenergic blockers are the pharmaceuticals recommended by the
professional practice guidelines to lower the mortality and rates of
hospitalizations. Despite compelling scientiﬁc evidence and
readily accessible national guidelines, beneﬁcial treatments of
HF remain underused and gaps and variations among facilities
have been reported. Optimizing treatments according to the
guidelines is one of the important components of multidisciplinary
team management. Registries to improve performance, such as the‘‘Organized Program to Initiate Life-Saving Treatment in Hospital-
ized Patients With Heart Failure (OPTIMIZE-HF)’’ [43], ‘‘Get with
the Guidelines-Heart Failure (GWTG-HF)’’ [44], and the IMPROVE
HF [45] were designed to implement several clinical decision
support tools to facilitate each stage of HF care. OPTIMIZE-HF is an
in-hospital initiation program, while IMPROVE HF is an ambulato-
ry care setting program [46]. Not only are the prescription rates of
medications recommended by the guidelines insufﬁcient, but also
beta-adrenergic blockers are sometimes under-prescribed. One
strategy to improve the prescription of beta-adrenergic blockers
might be a titration directed by nurses. Driscoll et al. reported that
an outpatient nurse-lead titration resulted in target doses and, in
turn, in lower rates of all-case hospitalizations and mortality [47].
On the other hand, in certain situations such as end-stage HF, it
may be preferable to lower the doses of ACE inhibitors and beta-
adrenergic blockers recommended by the practice guidelines or
withdraw therapy altogether, especially if they cause adverse
effects or lower the QOL. The discontinuation of ACE inhibitors or
angiotensin receptor blockers may be justiﬁed if a patient in end-
stage HF develops azotemia or symptomatic hypotension. Howev-
er, the impact of discontinuing therapy recommended by the
guidelines in patients with end-stage HF needs further studies.
Daily instructions in the Japanese culture
HF management includes sodium and water restrictions, as an
excessive intake of salt and water worsens the congestive signs and
symptoms. However, there are no deﬁnitive recommendations
regarding appropriate amounts of water and salt [48]. The sodium
limit recommended by the guidelines of the Heart Failure Society
of America is 2 g/day [37]. The American College of Cardiology
(ACC)/AHA guidelines recommend a sodium intake of 3 g/day [49],
while the ESC guidelines offer only vague recommendations
[38]. The level of evidence to support the recommendations is
listed as level C, Expert Opinion, indicating that the supporting
evidence is limited. Recently, a 3-g dietary sodium restriction has
been associated with a longer event-free survival in patients in
New York Heart Association (NYHA) class III or IV [50]. In Japan,
adults consumed an average of 4.89 g of sodium daily in 2010
[51]. However, a strict salt restriction may cause a loss of appetite
and interfere with QOL.
Water restrictions are also important, as an increase in body
weight begins 1–2 weeks before hospitalizations for HF [52]. Im-
portantly, the standard management of ambulatory patients
suffering from HF includes 2 to 12 ofﬁce visits or hospital-based
follow-ups a year. Therefore, an increase in body weight might not
be recognized by the caregivers. While the effects of diuretics on
prognosis are unclear because of the lack of clinical trials, they are
used to relieve pulmonary congestion, dyspnea, and peripheral
edema. A ﬂexible diuretic dosing regimen by monitoring conges-
tion might be a reasonable means of ambulatory management
[53]. However, there are limitations to the monitoring of
symptoms and daily weight. Home monitoring might be a better
strategy for the management of HF than these conventional signs
to identify subclinical congestion [54]. Recently, Philipson et al.
reported that a ﬂuid restriction to 1.5 L daily and salt restriction to
5 g daily lowered the NHYA class, and decreased the amounts of
edema, without negative impact on thirst, appetite, and QOL in
patients with moderate to severe HF and signs of ﬂuid retention
[55]. The Japanese summer is hot and humid and the amounts of
perspiration might be greater than in winter. Therefore, the water
restrictions in Japan should be seasonal, to avoid hyperthermia in
summer.
The Japanese have a habit of taking a warm water bath daily.
However, Tei et al. reported that the deep immersion and thermal
stress of a warm bath may further increase the intracardiac
Fig. 2. Ideal palliative care in patients with heart failure (HF). Without palliative
care, patients in end-stage HF suffer from severe dyspnea, which might further
activate the sympathetic system and trigger life-threatening arrhythmias,
respiratory or cardiac arrest, and death. An ideal palliative care with
conventional medical therapy might relieve dyspnea and attenuate the
activation of the sympathetic system, limit the risk of fatal arrhythmias and,
ultimately, prolong survival. This concept should be studied in the future.
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reported that a form of thermal therapy, using a dry sauna for
15 min at 60 8C, improves hemodynamic and vascular endothelial
functions in patients with HF [57]. Some hospitals use this as
adjunctive therapy.
Dietary interventions
The dietary instructions should be based on an adjustment of
the calories and consumption of appropriate amounts of fruits,
vegetables, whole grain, and ﬁsh [58]. Fruits, vegetables, and ﬁsh
oil have anti-inﬂammatory properties, which have been reported
to lower the rates of adverse cardiovascular events, whereas the
consumption of trans- or saturated fats may precipitate these
events [59]. The dietary education of patients must be repeated
and reinforced throughout the care of HF.
Since obesity is a known risk factor [60], adjustments in body
weight are critical in the prevention of HF. However, cardiac
cachectic patients suffer the highest mortality. The prevalence of
cardiac cachexia among patients suffering from HF is 5–15%
[61,62]. A decrease in food intake and anorexia results in a loss of
body mass. Furthermore, the activation of the sympathetic nervous
system, inﬂammatory cytokines, insulin resistance, and low levels
of anabolic hormones result in muscle wasting [61,62]. Inﬂamma-
tory cytokines and the activation of natriuretic peptides also
induce lipolysis [63]. The bone undergoes constant remodeling and
may be wasted during cardiac cachexia. A low bone mineral
density has been observed in patients presenting with advanced
chronic HF [64]. Therefore, the prevention, early diagnosis, and
treatment of cachexia are critical and recent guidelines by the ACC/
AHA have highlighted the importance of weight loss [49], although
no deﬁnitive remedy has been described [65]. The effect of high
calorie, protein-rich, oral, nutritional supplements has been
reported for patients with chronic HF and cachexia. Patients in
the intervention arm consumed an additional 600 kcal per day,
consisting of 20 g of protein, 72 g of carbohydrates, and 26 g of fat.
Body weight, fat mass measured by dual X-ray absorptiometry, and
serum cholesterol level increased, accompanied with a preserved
QOL and decreased serum concentration of tumor necrosis factor
[66]. These observations support a mitigation of inﬂammation by
nutrition-induced lipid modiﬁcations [67].
Palliative care
Despite the treatments recommended by professional practice
guidelines, including ACE inhibitors and beta-adrenergic blockers,
the morbidity and mortality of patients who are in advanced HF
have not decreased. Palliative care is a multidisciplinary means of
optimizing QOL and managing symptoms that does not exclude
medical therapy, and takes into account the physical, psychologi-
cal, and spiritual preferences and needs of patients and their
relatives [7–9]. Since palliative care has long been primarily
associated with the support offered for advanced, incurable cancer,
cardiologists and cardiac nurses are often unfamiliar with its
principles and practices, which aim at relieving suffering by a
multidisciplinary approach. In a recent study, the survival of
patients with end-stage cancer was unexpectedly prolonged [68].
The ACC/AHA HF guidelines recommend palliative care as level
of evidence 1A [49]. The guidelines state that aggressive
procedures that do not contribute to recovery or improve QOL
in the last several months of life, including intubation and
implantation of an ICD, are not appropriate. However, the
guidelines do not speciﬁcally address when palliative care should
begin. In the guidelines issued by the ESC, the patients for whom
palliative care should be considered are (a) frequently admitted to
the hospital or suffer major episodes of cardiac decompensationdespite optimal treatment, (b) not candidates for heart transplan-
tation or mechanical circulatory support, (c) chronically suffering
from a low QOL and are in NYHA functional class IV, (d) cardiac
cachectic with low serum albumin, (e) dependent for most
activities of daily living, and (f) judged to be clinically near the
end of life. Key components of palliative care service are (a)
frequent assessments of the patient’s physical, psychological, and
spiritual needs, (b) a focus on the complete relief of manifestations
of HF and concomitant disorders, and (c) advanced care planning,
taking into consideration the preferred places of death and
resuscitation [38].
HF is characterized by unpredictable bouts of decompensation
and stabilization, with a gradual decline over time. This represents
a challenge for caregivers, who must decide when the time has
come to refer a patient to palliative care. However, future palliative
care strategies might ideally preserve QOL and prolong survival
(Fig. 2).
Ambulatory and home-based infusions of inotropes
Despite the alleviation of symptoms and increase in exercise
tolerance observed with the administration of inotropes, a
retrospective analysis of the ADHERE registry found a signiﬁcantly
higher in-hospital mortality associated with the short-term
administration of dobutamine or milrinone [69]. However, the
continuous or intermittent infusion of inotropes at home or in an
ambulatory medical facility can be palliative for patients suffering
from advanced HF, who are not candidates for mechanical support
or cardiac transplantation. In absence of a survival beneﬁt, the ACC/
AHA guidelines classiﬁed intravenous inotropes as a class IIb
indication for end-stage HF [49]. Multiple studies have been
published on the use of intermittent inotropic drug infusions in
patients presenting with advanced HF from the perspective of
maintaining exercise ability and QOL [70,71]. However, in a
randomized trial, infusions of nesiritide, a putative organ protec-
tive natriuretic peptide, lowered neither mortality nor the rates of
hospitalization [72]. Moreover, 4–6 h infusions of nesiritide alone,
twice weekly, did not signiﬁcantly lower all-cause mortality or
hospitalizations for cardiovascular or renal complications in
patients with advanced HF in the FUSION II trial [73].
Fig. 3. Effects of ambulatory, intermittent infusion therapy in our institution. If the patient’s blood pressure is low, dobutamine or dopamine is used. If the blood pressure is
high, nitrates or carperitide (recombinant atrial natriuretic peptide) is used. Intermittent infusion therapy reduced the numbers and days of hospital admission and lowered
the medical costs.
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where a single inotrope or natriuretic peptide was administered,
our institution chose among different drugs with each infusion,
depending on the baseline systolic blood pressure. This strategy
decreased the number, length, and costs of hospitalizations (Fig. 3)
[74].
Management of dyspnea and pain
Patients presenting with end-stage HF suffer from unbearable
dyspnea, pain, and mental confusion. The use of intravenous
morphine in the treatment of pulmonary edema remains
controversial. The HF guidelines issued by the ESC advocate the
use of intravenous morphine in severe HF, to relieve anxiety,
restlessness, and chest pain [38]. In contrast, the ACC/AHA HF
guidelines reserve morphine for palliative care of end-stage
disease [49]. In a retrospective study, the use of morphine was
associated with a lower survival in patients with acutely
decompensated HF [75]. However, it may lower the pre- and
afterload and cause central nervous system, decrease the severity
of dyspnea, and attenuate the activation of the sympathetic
nervous system. Multiple studies have found opioids to be safe and
effective in the management of dyspnea, in doses typically smaller
than those used for the management of cancer. Oral morphine, 2.5–
5 mg/day, was safe and effective for the relief of breathlessness in
patients presenting with chronic HF [76]. Continuous morphine
infusions have also been administered to patients with intractable
dyspnea. However, Setoguchi et al. found that patients dying of HF
are less likely to be supported by hospices and opiates [77]. This
might be explained by the unwillingness of patients and relatives
to accept their limited life expectancy, while, on the other hand,
medical efforts might improve the condition of patients who are in
end-stage HF. In addition, some may be afraid that morphine might
depress the central nervous system and control of respiration,
which might lower the life expectancy.
Pain is common and undertreated in end-stage HF. Non-
steroidal anti-inﬂammatory drugs are not recommended, because
of the risk of gastrointestinal bleeding, renal failure, and ﬂuid
retention. Opioids should be used for moderate to severe pain.
Fentanyl might also be considered. Moreover, HF might be
complicated by recurrent or persistent mental confusion and,sometimes, agitation. The environment should offer sufﬁcient
sunlight during daytime, while sleep should be undisturbed at
night, using small doses of haloperidol, if necessary. Rutten et al.
reported that at the end of life, 35% of nearly 400 HF patients
received opioids and 7% received haloperidol [78]. In Japan,
midazolam might be considered for sedation [79].
Resuscitation
The decision about cardiopulmonary resuscitation is initially
presented as a decision of whether to allow natural death or
resuscitation. ICD lower the likelihood of sudden cardiac death due
to arrhythmias. However, no study has demonstrated a survival
beneﬁt conferred by ICD in patients presenting in NHYA functional
class IV. As HF worsens, patients are likely to receive more frequent
shocks, which cause considerable pain and anxiety. The deactiva-
tion of ICD, when death is near, is advisable to prevent repetitive
shocks. Unlike ICD, cardiac resynchronization therapy improves
QOL. Therefore, it may be appropriate to continue biventricular
stimulation when the decision has been made to turn off an ICD.
Kinch Westerdahl et al. reported that ICD recipients often die in the
hospital, and one-third developed ventricular tachyarrhythmias
treated with shocks delivered close to death [80]. Over 50% of
patients had an order to not resuscitate, of whom over 50% had
shock therapy programmed ‘‘ON’’ 1 h before death, enabling the
unnecessary and painful administration of shocks to dying
patients. In Japan, a statement regarding end-stage HF was
released in 2010 by the Japanese Circulation Society [81]. However,
the understanding of end-stage HF by cardiologists and nurses has
not been discussed in depth [82].
Conclusion
To the best of our knowledge, this is the ﬁrst review of
multidisciplinary management of HF published in Japan. However,
most reference papers for HF are derived from Western countries
and populations, and few references are available from Japan, since
the multidisciplinary management of HF has just begun in Japan.
Therefore, some caution should be exercised when applying
clinical management practices from other countries to Japanese
patients. From a national perspective, Japan is a small country, and
Y. Sato / Journal of Cardiology 66 (2015) 181–188 187access to hospitals is easier as compared to that in other large
countries. Japan is third on the list of gross national incomes, and
its high medical cost is supported by a robust governmental
medical insurance system. Further, the environment and climate
also differ from those of other countries, with various seasonal
changes. The religion is also different from that in Western
societies. Finally, the life expectancy of the Japanese is longer than
that of most other countries. Taking these factors into account, a
carefully tailored Japanese version of HF management needs to be
developed for its unique social environment.
From the perspective of each individual and institute, there is a
wide variability in multidisciplinary team management for any
disease condition. From the patients’ perspective, there are widely
variable incomes, health literacy [83], and social and familial
support. At a geographical level, access to medical institutions may
be limited. From an institutional perspective, there is variability in
time, resources, and staff expended for multidisciplinary manage-
ment. All these factors inﬂuence the course of HF and diversify the
resulting multidisciplinary management.
Finally, the number of patients with HF is increasing; therefore,
a seamless multidisciplinary approach is critical for patients to
convert from in-hospital to out-hospital [14–19]. However, few
studies have been published in Japan from the perspective of
outpatient bases [20,21]. Future management systems that include
home-based doctors and nurses are necessary along with hospital-
based ones.
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